Chemical Name: spiro[imidazo[1,2-a]pyridine-3,2-indan]-2(3H)-one
Therapy Type: Small Molecule
Target Type: Unknown
Condition(s): Alzheimer's Disease
U.S. FDA Status: Alzheimer's Disease (Inactive)
Company: Sonexa Therapeutics, Inc.
ST101 is an azaindolizinone derivative that likely has diverse effects. It has been shown to induce APP cleavage at a novel site novel site, generating a 17 kDa C-terminal fragment. This cleavage event precludes Aβ generation (Green et al., 2011). ST101 has also been shown to activate a number of intracellular signaling pathways such as ERK1/2 following stimulation with dopamine D1 and NMDA receptors (Ito et al., 2007).
ST101 has been shown to improve the memory deficits observed in mice following olfactory bulbectomy (Han et al., 2008).
- Han F, Shioda N, Moriguchi S, Yamamoto Y, Raie AY, Yamaguchi Y, Hino M, Fukunaga K. Spiro[imidazo[1,2-a]pyridine-3,2-indan]-2(3H)-one (ZSET1446/ST101) treatment rescues olfactory bulbectomy-induced memory impairment by activating Ca2+/calmodulin kinase II and protein kinase C in mouse hippocampus. J Pharmacol Exp Ther. 2008 Jul;326(1):127-34. PubMed.
- Green KN, Khashwji H, Estrada T, Laferla FM. ST101 induces a novel 17 kDa APP cleavage that precludes Aβ generation in vivo. Ann Neurol. 2011 May;69(5):831-44. PubMed.
- Ito Y, Takuma K, Mizoguchi H, Nagai T, Yamada K. A novel azaindolizinone derivative ZSET1446 (spiro[imidazo[1,2-a]pyridine-3,2-indan]-2(3H)-one) improves methamphetamine-induced impairment of recognition memory in mice by activating extracellular signal-regulated kinase 1/2. J Pharmacol Exp Ther. 2007 Feb;320(2):819-27. Epub 2006 Nov 7 PubMed.
No Available Further Reading